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Abstract
Background: Throughout the last decade, tuberculosis (TB) treatment success has not surpassed 90%, the global
target. The impact of mobile health interventions (MHIs) on TB treatment outcomes is unknown, especially in low-
and middle-income countries (LMICs). MHIs, including interactive voice response technology (IVRT), may enhance
adherence and retention in the care of patients with tuberculosis and improve TB treatment outcomes. This study
seeks to determine the impact of IVRT-based MHI on TB treatment success (treatment completion and cure rates) in
patients with TB receiving care at five public health facilities in Uganda.
Methods: We used a theory-based and human-centered design (HCD) to adapt an already piloted software to
design “Call for life-TB” (CFL-TB), an MHI that utilizes IVRT to deliver adherence and appointment reminders and
allows remote symptom reporting. This open-label, multicenter, randomized controlled trial (RCT), with nested
qualitative and economic evaluation studies, will determine the impact of CFL-TB on TB treatment success in
patients with drug-susceptible TB in Uganda. Participants (n = 274) at the five study sites will be randomized (1:1
ratio) to either control (standard of care) or intervention (adherence and appointment reminders, and health tips)
arms. Multivariable regression models will be used to compare treatment success, adherence to treatment and
clinic appointments, and treatment completion at 6 months post-enrolment. Additionally, we will determine the
cost-effectiveness, acceptability, and perceptions of stakeholders. The study received national ethical approval and
was conducted in accordance with the international ethical guidelines.
Discussion: This randomized controlled trial aims to evaluate interactive voice response technology in the context of
resource-limited settings with a high burden of TB and high illiteracy rates. The software to be evaluated was
developed using HCD and the intervention was based on the IMB model. The software is tailored to the local context
and is interoperable with the MHI ecosystem. The HCD approach ensures higher usability of the MHI by integrating
human factors in the prototype development. This research will contribute towards the understanding of the
implementation and impact of the MHI on TB treatment outcomes and the health system, especially in LMICs.
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Introduction
The burden and impact of TB on low- and middle-
income countries (LMICs) is unprecedented. TB is the
leading infectious cause of death worldwide [1]. The
disease is one of the leading causes of hospitalization [2]
and in-hospital mortality in sub-Saharan Africa [2, 3].
LMICs contribute more than 80% to the global inci-
dence of TB [1]. The high burden in LMICs is mainly at-
tributable to HIV [4], poverty [5], and weak health
systems [6]. Despite the high burden, health systems in
LMICs are unprepared to contain the epidemic. Adher-
ence and retention in TB programs are low [7, 8], which
hampers TB control efforts. Modeling studies suggest
that strengthening the TB care cascade could reduce TB
incidence by more than 30%. However, there are limited
data on the role and impact of mobile health interven-
tions (MHI) in strengthening TB care systems [9].
Mobile phone use and access to the Internet are asso-
ciated with a reduction in TB incidence and mortality
[10]. The impact of mobile health technologies on the
enhancement of infectious disease services has been
demonstrated globally [11, 12]. The WHO’s “End-TB
strategy” emphasizes the use of MHIs to accelerate the
implementation and monitoring of TB services [13] and
has recommended the application of MHIs to improve
adherence to treatment [14]. The rapid growth in the
mobile phone industry has transformed health systems
across many LMICs [15–17]. Therefore, the increasing
mobile phone ownership in LMICs, including in HIV/
TB clinics [18, 19], offers an opportunity to strengthen
health systems and ensure the delivery of patient-
centered care. This may improve patient retention in
care and treatment adherence, ultimately improving TB
treatment outcomes [20]. MHIs are acceptable to people
with chronic infections in several LMICs [21–23], and
the infrastructure for their use is improving in many
LMICs, including Uganda [24].
The majority of phones used in LMIC are feature
phones (non-smart), which are not compatible with the
technologies that have been demonstrated to enhance
TB care in developed countries [25]. In LMICs, the
evidence for the impact of MHIs on TB treatment
outcomes is limited to studies involving short message
service (SMS) interventions. Although SMS interven-
tions seem to be generally associated with higher
treatment success [26], the results from LMICs have
been contradictory. Some studies have reported a signifi-
cant impact on treatment success [12] while others did
not find better treatment outcomes with SMS interven-
tions [27–29]. The implementation of SMS MHIs is low
in LMICs because of high illiteracy and preference for
voice-based communication [30–32]. Interactive voice
response technology (IVRT) delivers voice calls that do
not require reading skills. Therefore, IVRT may be
acceptable and may have a greater impact. While
there is increasing evidence for use of IVRT to
optimize care in people receiving HIV care and other
health services [33–35], no study has evaluated the
impact of mobile-based IVRT on TB treatment out-
comes in Africa. We used the information, motiv-
ation, and behavioral skills (IMB) model of behavioral
change [36] to guide the design of an IVRT-based
technology that enhances adherence to TB treatment.
The IMB model was initially developed to modify
HIV-risky behaviors and has now been adopted to
guide behavioral change in developed countries [34].
The model suggests that the motivation of TB pa-
tients, increasing adherence skills, and providing in-
formation on TB treatment would improve adherence.
The model was used to target increase adherence and
retention in care since improving these aspects may
increase treatment success (Fig. 1).
Owing to the novel approach of IVRT for TB, in this
paper, we document our protocol to inform the body of
work around the MHI for TB. Furthermore, given the
complexity of MHI and its capacity at multiple behav-
ioral levels, we will be undertaking an interdisciplinary
study with qualitative, quantitative, and economic
components.
Research objectives
The primary objective of this study is to determine the
impact of an IVRT software (CFLU-TB) on treatment
success in patients receiving treatment at public facilities
in Uganda. The secondary objectives were as follows:
1. To compare TB cure rates (six months) in patients
with microbiologically diagnosed TB in the
intervention and control arms.
2. To compare treatment completion (six months) in
patients clinically diagnosed with TB in the
intervention and control arms.
3. To determine the effect of enhanced TB treatment
support with CFLU-TB on retention at 2 and 6
months in patients receiving TB treatment.
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4. To assess the perception of patients’ care providers
(treatment buddies) and other stakeholders about
CFLU-TB.
5. To determine the cost-effectiveness of the
intervention.
6. To compare adherence rates between patients in
the intervention arm and control arms.
7. To determine the effect of CFLU-TB on adherence
to clinic appointments.
8. To compare knowledge about TB/HIV in patients
enrolled in the intervention and control arms.
9. To determine Drug-resistant TB rates in the
intervention and control arms.
10. To determine the uptake of the CFLU-TB tool in
patients and their care providers (treatment
buddies).
Study hypothesis
We hypothesized that IVRT will have a 10% higher im-
pact on treatment success than SMS intervention; there-
fore, we predict that CFL-TB will lead to a 15%-point
increase in treatment success rate in the intervention
arm compared to the standard of care (control arm).
This is based on a previous RCT that reported 5–9%
better treatment success in patients who received SMS
adherence reminders versus the standard of care [12, 27].
Methodology
Trial design
This study will be an open-label, multicenter RCT in-
volving adult patients with drug-susceptible TB random-
ized (1:1 ratio) to either the intervention (adherence and
appointment reminders, health messages, and 24-h
health care worker call service) or control arm. The
study will have nested qualitative and economic evalu-
ation sub-studies and a process evaluation to determine
the uptake and use of the intervention.
Study settings
To ensure the generalizability of the results of this study,
we planned to enroll patients from several facilities that
are representative of typical TB facilities in Uganda.
Most patients with tuberculosis [37, 38] are treated at
low-level public facilities but a significant burden also
exists in urban settings [37, 38]. Therefore, we selected
both public and rural TB treatment facilities. Kisenyi
Health Center, the first study site, is a large public health
center situated within the oldest slum in Kampala which
is home to over 23,000 people vulnerable to TB. As a re-
sult, the facility receives about 25 new TB patients per
month. In addition, Kiryandongo is a rural agrarian dis-
trict hospital that serves 266,000 people, including 50,
000 refugees. The hospital registers an average of 9 new
TB cases per month. In contrast, Kasangati Health
Center IV is a busy peri-urban facility that serves the
Kyadondo East in the Wakiso district and attends to ap-
proximately 24 new TB cases per month. To expedite
participant accrual, two additional facilities were added
to the study protocol version 2.0. Bweyogerere and
Kawanda Health Centre IIIs are in the Wakiso district
and serve a peri-urban population. They treat approxi-
mately 12 patients with TB each per month.
At all health facilities [39, 40], patients with at least
one of the dangerous symptoms of TB are offered a
Fig. 1 Behavioral change conceptual framework for the study, adapted from Informational Motivation- Behavioral skills model (Fisher, W. A., &
Fisher, J. D. (2009))
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sputum GeneXpert test while those unable to expector-
ate are offered alternative diagnostic tests (CXR, TB
LAM, sonography, tissue biopsy, CSF analysis, etc.).
Patients with sputum-positive TB are then tested for
rifampicin resistance using the GeneXpert MTB Rif
assay [40].
Control arm and the standard of TB care in Uganda
The standard of care at all TB treatment centers follows
the national TB treatment guidelines [40]. The standard
treatment duration is 6 months, except for patients with
TB meningitis and osteoarticular TB who require 12
months of treatment. The standard regimen and dur-
ation of treatment for patients with drug-susceptible TB
are 2 months for isoniazid, ethambutol, rifampicin, and
pyrazinamide, followed by four months of rifampicin
and isoniazid [34]. Patients are reviewed every 2 weeks
for the first month and monthly thereafter. All patients
are encouraged to register a close household or commu-
nity member to directly observe therapy, but this is not
enforced. Patients receive health education during clinic
visits with messaging on adherence and treatment com-
pletion. At treatment initiation, patients are routinely
encouraged to adhere to treatment and appointments,
but there are often no patient support systems provided
to enhance this. Some patients may use other reminder
systems of their choice [41] but this has not been de-
scribed in patients with TB.
Description of the proposed mobile health intervention
The technology to be evaluated in this study is Call for
Life-TB (CFL-TBTM), a software that is based on open-
source mobile technology for community health
(MoTeCH) [42]. MoTeCH was initially developed by the
Grameen Foundation and the University of Southern
Maine with the support of Janssen, the Pharmaceutical
Companies of Johnson and Johnson. It was designed as a
community MHI platform to improve treatment compli-
ance in patients in LMICs [42, 43]. We then adapted
and evaluated the technology to support people living
with HIV in Uganda and named it Call for Life TM
(CFL) [34]. CFL-TB uses interactive voice response
(IVR) or short messaging service (SMS) to communicate
with PLHIV via mobile phones [34]. This prototype,
“Call for Life-Uganda”, was iteratively adapted to design
CFL-TB, a technology tailored to address the needs of
patients with TB. The needs of patients with TB were
enumerated through discussions with health workers
and patients at IDI HIV/TB clinics. The software was se-
quentially upgraded, and the subsequent versions were
reviewed by end-users at each stage. End-users (study
staff and patients with TB) reviewed the software for
suitability and suggested changes. Overall, the changes
were aimed at optimizing the usability and security of
the software. Participants in the intervention arm will re-
ceive standard of care plus CFL-TB enhanced TB care,
and those in the control arm will receive standard of
care.
The intervention (CFL-TB)
CFL-TB delivers once-daily adherence reminders, pre-
appointment reminders, and targeted educative behavior
change messages and allows patients to report symptoms
to health care workers (HCWs) remotely. As advised by
Iribarren et al., participants will decide their preferred
language and the timing and frequency of reminders and
will ensure that the content is culturally sensitive [44].
The software also delivers calls to registered care pro-
viders (buddies) of patients to facilitate daily observed
therapy (DOTS), in line with the World Health
Organization and Ministry of Health guidelines [14, 40].
In Uganda, daily reminders are generally preferred by
patients over weekly reminders [8]. To increase adher-
ence to the intervention, if the first call is not answered,
the system will make two additional calls, 15 min apart.
The study staff will also interview participants in the
intervention arm to determine whether they are experi-
encing any problems. Health care workers enroll patients
in the system, monitor the delivery message delivery of
messages, and provide ongoing technical support, such
as setting personal identification numbers (PINs) and
swapping the registered telephone numbers. In contrast,
participants are responsible for making and receiving
calls. We will synchronize appointment reminders with
scheduled appointments, and the software will initiate a
call before and on the day of the clinic review. Partici-
pants select their preferred time to receive the reminder
calls and set their PIN. The system offers short educa-
tional messages to increase knowledge about TB/HIV
and general health [40]. The CFL-TB software is inter-
operable with other health information systems used in
Uganda, including DHIS2, a web-based database for
health reporting.
Study population and eligibility criteria
This study will enroll adults (≥ 18 years) who were newly
diagnosed with drug-susceptible TB (Fig. 2). The de-
tailed eligibility criteria include the following:
Inclusion criteria
1. Evidence of TB diagnosis either confirmed
bacteriologically by Xpert MTB/RIF Version G4
assay (Cepheid, Sunnyvale, CA, USA) or clinically
diagnosed.
2. Evidence of a personally signed and dated informed
consent document that indicates that the
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participant (or a legal representative) has been
informed of all pertinent aspects of the study.
3. Willingness to comply with scheduled visits,
treatment plans, laboratory tests, and other study
procedures.
4. Aged ≥ 18 years
5. Mobile phone ownership. Subject to funding, study
participants without mobile phones may be
provided with mobile phones.
6. Patients who can understand Luganda, Runyankore,
Swahili, or English. These languages are the
languages spoken by most patients at the study
health facilities. If we add Lira RRH as a study site,
we will add Luo, the predominant language spoken
in the Lango region. Other languages may be added
to the service if the anticipated demand surpasses
30 patients.
Exclusion criteria
1. Inability to use a basic feature phone or presence of
a clinical condition that interferes with appropriate
use of the mobile phone for voice calls (e.g.,
deafness, severe cognitive impairment)
2. Ongoing participation in another interventional
study that the investigator believes will interfere
with study procedures or assessment of the
outcomes of this study.
3. Patients who are critically ill.
4. Patients with drug-resistant TB (Rifampicin
resistant, Multi-drug resistant, and extensive drug-
resistant TB).
5. Patients with TB meningitis or osteoarticular TB.
6. Any other clinical condition that, in the opinion of
the site investigator, would make the participant
unsuitable for the study or unable to comply with
dosing requirements.
Recruitment of study participants and strategies for
achieving adequate participant enrolment
This study will recruit from TB clinics within the study
clinics. The study staff will identify participants newly
diagnosed with TB. To expedite participant accrual, two
additional facilities have been added to the study
Fig. 2 CONSORT Flow Diagram
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protocol version 2.0. Bweyogerere and Kawanda Health
Centre IIIs are in the Wakiso district and serve a peri-
urban population. They receive an average of 13 and 10
patients with TB per month (approximately 156 and 120
patients per year, respectively). Additionally, study initi-
ation meetings have been conducted with health facility
staff and patients at all study sites study to increase
awareness about the study. We hope this enhances the
referral of participants to the study.
Randomization, blinding, and allocation concealment
At baseline, participants will be randomly assigned (1:1 ra-
tio) to either the intervention or control arms (Fig. 2). The
study statistician generated study allocation slips for par-
ticipants for each study site using and these are then
enclosed in sealed opaque envelopes. The number of cards
allocated per study site will be equal to the enrolment
target assigned to the study site. The allocation slips will
indicate either the intervention or the control arm. The
study arm will be allocated by drawing one envelope by a
participant from a closed envelope box. Patients will ran-
domly pick and open an envelope and they will be allo-
cated a study arm that is indicated on the enclosed card.
Since the opaque envelopes will be used and drawn from
a closed opaque box, the allocation sequence is concealed
from the recruiting study staff. We will maintain screening
and enrolment logs at each study site to ensure that there
is no bias in randomization and enrolment. Due to the
study design involving voice reminders to participants, it
is not possible to blind participants. However, the analyz-
ing statistician will be blinded to the allocated arms.
Participant follow-up, procedures, and timelines
Participant follow-up before six months, the total study
duration is 24 months, and participants will have
evaluations at baseline and months 2, 5, and 6, consist-
ent with the Ministry of Health visit scheduling for pa-
tients with TB (Table 1). At each visit, the participants
will be given their future appointment dates.
Participant withdrawal and post-trial care
Participants can be withdrawn from the RCT at their re-
quest, following death or disengagement from care. Par-
ticipants may also be withdrawn at the discretion of the
investigator for safety concerns. If the subject withdraws
from the RCT, the study staff will not perform further
evaluations, and data collection will cease. The RCT will
retain data collected before withdrawal unless the par-
ticipant requests otherwise. Study staff will track partici-
pants who miss visits. If a participant does not attend for
two consecutive months, they will be considered lost to
follow-up (attrition). All withdrawn participants will be
linked to the standard of care. Participants with cured
TB will be exited from care while those with no evidence
of cure will be linked to tertiary TB services at their
treatment facilities. At the end of the RCT, participants
will have their treatment details updated in the TB regis-
ter and are discharged from care.
Data collection and management
We will comply with the Ugandan laws on data privacy
and management [45]. Data will be entered using RED-
cap [46]. The system automatically flags missing and
out-of-range values, which will be attended to by the
RCT staff.
Data collection
At baseline, the staff will obtain sociodemographic data
(age, sex, marital status, level of education, employment
status, income, transport costs, distance from the
Table 1 Study timelines and procedures
Study procedures Study procedure completed
Month 0 0 2 2 5 5 6 6
Study arm I C I C I C I C
Screening √ √
Informed consent √ √
Physical evaluations and interviews √ √ √ √ √ √ √ √
Demographic and socio-economic questionnaire √ √ √ √ √ √ √ √
Sputum GeneXpert* √ √ √ √ √ √
Drug culture and susceptibility testsβ √β √β √β √β √ √ √β √β
Cost-effectiveness questionnaire √ √ √ √ √ √ √ √
Qualitative assessment √ √ √ √ √ √
Note: I-Intervention arm, C-control arm
*Additional tests to ascertain sputum conversion may be added at the discretion of the investigator.
βDrug susceptibility testing will be done in-line with national TB guidelines. Sputum cultures may be done at 2 months to ascertain sputum conversion and
sputum for genotyping TB stored.
√ indicates procedure completed at the indicated timeline
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facility) and data on TB infection (method of diagnosis,
site of infection, and rifampicin resistance at baseline).
Prospectively, data will be obtained on adherence,
symptoms, sputum tests, missed appointments, and
clinic visits (Table 1). Participants will also be inter-
viewed on phone call costs, hospitalization, and over-
the-counter treatments. At baseline, we will interview
patients (qualitative data) on their anticipated challenges
in the use of IVRT and anticipated benefits and chal-
lenges. At months 2 and 6, qualitative data will be col-
lected on acceptability and experience with the digital
intervention. We will determine the sputum conversion
rate at 2 months and cure at 6 months. Chest radio-
graphs will be used to determine the cure for patients
with clinical TB. TB cards and treatment registers will
be reviewed for death, adherence, and date of patient
visits. We will use micro-costing to obtain data on the
direct and indirect costs.
Trial endpoints
The primary endpoint is treatment success (at 6
months): treatment success is a composite outcome,
comprising treatment completion and cure in patients
with clinically and bacteriologically diagnosed TB, re-
spectively. It is a robust and agreed indicator of treat-
ment success in TB programs. In patients with
bacteriologically diagnosed TB, cure is defined as having
a negative sputum test in the last month of treatment
and on at least one previous occasion [47]. For clinically
diagnosed patients, completion entails 6 months of ther-
apy. The denominator for each arm will be the number
of patients enrolled. At the same time, the numerator is
the sum of bacteriologically and clinically diagnosed pa-
tients with cure or treatment completion, respectively.
This RCT also has several secondary endpoints. First,
we will determine the TB cure rates in patients with
microbiologically diagnosed TB. Second, we will deter-
mine treatment completion for patients clinically diag-
nosed with TB in the two arms: Third, retention rates
will be determined and compared between the study
arms. Patients will be deemed to be actively engaged in
care if they attend a clinic visit within one month of a
scheduled appointment. Additionally, we will compare
appointments. We will categorize visits as “early,” if they
present before an appointment, “prompt” if they show
up within three days after the appointment date, “late” if
they present after three days but within 30 days of a
scheduled appointment and missed if patients do not
show up at all or present after 30 days. Fourth, we will
determine the incremental costs per additional DALY
averted per percentage point increase in treatment
success in the intervention versus the control arm. In
addition, we will compare adherence rates at months 2
and 6. Depending on the availability of drug susceptibility
tests, we will compare the rates of MDR-TB. To under-
stand the impact of the intervention on the treatment out-
comes and the potential for adoption and scaling of the
intervention, we will explore the perceptions and experi-
ences of patients and care providers towards the MHI.
Finally, we will determine the uptake and adherence to
the intervention. We will consider the successful receipt
of a reminder as a proxy for the utilization of the technol-
ogy. Therefore, we will determine the proportion of
successful calls in the intervention and control arms.
Sample size determination
Based on results from a randomized controlled trial in
Kenya that demonstrated a 9% increase in TB treatment
success following the use of SMS [12], we hypothesize
that the interactive voice response platform will lead to
at least a 6% higher impact as compared to SMS re-
minder treatment success (i.e., a 15%-point difference
compared to the control arm). A retrospective cross-
sectional study of routine data on HIV/TB co-infected
patients from the Uganda National Tuberculosis and
Leprosy Program reported lost to follow-up rates of
3.5% and 16.6% in urban and rural settings, respectively
[7]. The rate of lost-to-follow at the three TB clinics was
approximately 11.8%. Therefore, assuming an 11.8%
lost-to-follow-up rate, this study would require a mini-
mum of 274 (137 patients per arm) patients to demon-
strate a 15% increment in treatment success with a
power of 0.8 and precision of 0.05.
Analysis of endpoints
The planned analyses are summarized in Table 2. We
will use a two-tailed p value of 0.05 and report the 95%
confidence intervals for all endpoints. In all analyses, we
will control for confounders of adherence and retention
[7, 48, 49]. In both primary and secondary outcomes,
we will undertake per-protocol and intention-to-treat
analyses.
Analysis of the primary endpoint
We will use logistic regression to determine the crude
and adjusted odds ratios of treatment success in the
intervention arm versus the control arm. The multivari-
able model will adjust just for potential confounders, in-
cluding age, sex, employment status, bacterial load at
baseline, TB category, and HIV status [7, 48, 49]. The
stepwise backward elimination method will be used to
fit the final model. The model with the lowest Akaike in-
formation criterion (AIC) statistic will be considered the
best fitting. Covariates with a global/trend p value > 0.2
at the bivariate analysis, will be adjusted for in the final
multivariate model. We will explore factor interactions,
including the interaction between age adherence and
sputum smear results at baseline. Where interaction is
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confirmed, we report both the main and interaction
effects.
Analysis of quantitative endpoints
Logistic regression will be used to determine the ad-
justed odds ratio for TB cure and treatment completion
in the intervention arm versus control arms. We will
also determine the predictors of TB cure overall and in
both arms. The final model will adjust for age, sex, bac-
terial load, HIV status, TB site, and symptoms at base-
line. We will also determine and compare attrition in
the two study arms using the Cox proportional hazards
model. We will compute the crude and adjusted hazard
rates of attrition in the intervention and control arms.
The log-rank test will be used to test for differences in
attrition between the study arms. Tests for the Cox pro-
portional hazard assumption will be done graphically
using Schoenfeld residuals. The model will adjust for
age, sex, Karnofsky score at baseline, HIV status, trans-
port costs, distance from the health facility, TB site, and
socioeconomic covariates.
We will compare the mean adherence rates (propor-
tion of TB medicines taken as evidenced by TB card) at
6 months in the intervention and control arms. We will
treat adherence as a continuous covariate and compare
the median adherence between the intervention and
control arms. To compare appointment keeping, we will
use ordinal logistic regression to determine the adjusted
odds ratios of missed, late, and prompt visits (early used
as a reference group). In the sensitivity analysis, Poisson
regression will be used to compare the number of
missed visits and treatment doses in the intervention
and control arms. The models will adjust for age, sex,
employment, distance from the health facility, and HIV
status. We will use chi-square to compare the propor-
tions of patients with MDR-TB between the two study
arms. Additionally, logistic regression will be used to
determine the crude and adjusted odds ratios of MDR-
TB in the intervention and control arms. Finally, as a
proxy for the uptake of intervention and fidelity, we will
determine the proportions of successful and dropped
and received calls at three different (2, 4, and 6months)
to determine patient exposure and acceptance of the
intervention through the study treatment period.
Cost-effective analysis
For the determination of cost-effectiveness, we will fol-
low the WHO’s guidance on the economic evaluation of
TB interventions [50]. To this end, we will determine
the incremental costs per additional DALY averted per
percentage increase in treatment success. All costs and
DALYs derived from the models will be discounted at
3%, and a 5-year horizon will be used. The price year
used will be the first year of research implementation,
and a discount rate of 3% shall apply. We hope that this
intervention will be scaled up if it shows clinical effect-
iveness. Therefore, we model the overall programmatic
cost of implementing the intervention at scale.
We will use the societal perspective to determine the
cost-effectiveness of the intervention, assuming govern-
ment standard rates and costs. From the financial re-
cords of the project, we will abstract disaggregated data
on the costs (prevailing dollar rate in the year of imple-
mentation) of direct financial costs (micro-costing). To
determine the direct costs for scale-up, we will exclude
costs related to conducting research that would other-
wise not be met if the intervention is implemented ac-
cording to government standard cost.
We then model the cost-effectiveness of the interven-
tion by assuming 72% and 100% phone coverage in pa-
tients with TB. We will construct a decision-analysis
model using TreeAge® software (version 3.5, MA, USA)
to compare the cost-effectiveness of digital intervention
versus standard of care. The probabilities of cure and
Table 2 Analysis of quantitative outcomes
Outcomes Measure of outcomes (intervention versus control arm) Statistical analysis
Treatment success Proportion of patients with treatment success at six months. Odds ratio of
treatment success
Logistic regression, odds ratios
Cure rates Proportion of patients cured of TB; odds ratio of TB cure Logistic regression, odds ratios
Treatment completion Treatment completion rate; odds ratio of treatment completion Logistic regression, odds ratios
Retention in care Hazards of attrition in the intervention versus control; Cumulative attrition at six
months
Cox’s proportional hazards model,
log-rank test




Proportion of patients who keep an appointment; Proportion of patients with
early, prompt, and late visits
Ordered logistic regression
Drug-resistant TB rates Proportion of patients with rifampicin-resistant TB Logistic regression, odds ratios
Call success rates (2,4, and 6
months)
Proportion of successful calls t test
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treatment completion to be used in the software will be
obtained from the study (for intervention) and national
TB reports (for control arms). We will use the national
TB prevalence survey [38] to estimate the number of pa-
tients with TB nationally. The years of life lost (YLLs)
averted will be calculated by subtracting the median age
at death from TB from the estimated average life expect-
ancy at birth for Uganda. Regarding the determination
of YLL for HIV co-infected patients, a Markov model for
ART-experienced PLHIV will be fitted. The global bur-
den of disease estimates will be used to determine the
disability-adjusted life years (DALYs) weights for those
patients with TB and life expectancy at birth [51].
Qualitative analysis
We will explore the experiences of patients and stake-
holders while using the CFL-TB tool through focus
group discussions and key informant interviews. We will
use purposive sampling and continue data collection
until saturation is achieved [52]. Participants will be
stratified by gender, age, and use of the tool. We will use
the thematic analysis approach to determine what partic-
ipants and other stakeholders experience and perceive.
The conventional content analysis approach will be used;
the coding categories will be derived directly from the
text data [53]. Preliminary data analysis will occur con-
currently with the data collection. The process of proof-
reading transcripts and notes will help draw attention to
emerging and a priori themes. Themes then form a
framework for a codebook. During the coding process,
the codebook will be adapted and quotations that are il-
lustrative of participants’ perspectives and experiences
regarding the issues being studied will be identified and
used in the presentation of the findings. Using the di-
rected qualitative analysis approach [53], we will explore
the relationships between the intervention and treatment
outcomes using the IMB model [36] as a guide theory.
Sensitivity analysis
To determine the impact of nonadherence to the study
intervention, we will stratify the analysis by utilization of
the CFL-TB tool. For both primary and secondary
quantitative endpoints, we will conduct an overall and
stratified analysis by HIV status, TB type (pulmonary
versus other forms of TB), and gender.
Interim analysis
There will be no preliminary analysis, as this study does
not pose a significant risk to participants.
Ethical considerations
The study protocol was approved by the Makerere
University School of Medicine Research Ethics Commit-
tee (SOMREC) (Approval #:2019-149) and the Uganda
National Council of Science and Technology (UNCST)
((Approval #: HS524ES). Any protocol amendments will
be reviewed and approved by SOMREC and UNCST.
Therefore, we will follow the UNCST guidelines [45, 54],
the Declaration of Helsinki [55], and good clinical prac-
tice [56] during the study implementation. Before par-
ticipation, the study staff will screen and obtain written
informed consent from all prospective participants and
their care providers. There will be no additional require-
ment for consent before obtaining biological specimens,
including blood samples and sputum, as these are part
of the standard of care.
Protocol amendments
The initial protocol (version 1.3, approval date Novem-
ber 07, 2019) (Supplementary File 1) was amended, and
protocol version 2.0 was approved by SOMREC and
UNCST on March 22, 2021. The major changes in-
cluded a provision for phone-based reviews and an add-
itional two study sites. Supplementary File 2 provides
details of the changes made in protocol version 2.0. The
latest approved protocol version 2.0 is provided as Sup-
plementary File 3.
Confidentiality of participant data
To ensure the safety of the participant data, data are
regularly entered into a database hosted on the IDI ser-
ver. The data on the CFL-TB backend were encrypted.
Access to the system database is password-protected and
inactivity for more than 30 min on the CFL-TB web
interface logs the web user out. The system generates a
log of admin logins and the changes to the web inter-
face. Patients calling on CFL-TB are authenticated by
their registered mobile number and must key-in their
PINs before listening in to the calls. The software does
not reveal its own identity to the person called until the
person has been authenticated as a registered patient
(only CFL-TB signature music is played). The Analysis
datasets will be anonymized before data analysis by
assigning participants with pseudo identification
numbers (IDs) delinked from the study IDs. Phone call
records will not be disclosed but may be used for match-
ing data.
Adverse events reporting
At each visit, participants will be interviewed on any on-
going symptoms and hospitalizations since their prior
visit. The CFL-TB platform will maintain a patient toll-
free number, and patients will be asked to initiate calls
when they want to communicate with HCWs. All ad-
verse events (AEs) will be graded using the Division of
AIDS (DAIDS) table for adverse events [57]. Serious
adverse events (SAEs) will be reported to IRBs. The
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investigator will assess the relatedness and causality of
AEs to mobile phone use.
Study oversight and monitoring
The design, implementation, and evaluation of this study
will be monitored by an independent scientific advisory
board (SAB). The SAB comprises eminent community
members, policymakers, scholars, and scientists. There
will be no data safety monitoring board, as the study
does not pose a significant risk to participants. Any
suggested protocol amendments will be reviewed by the
SAB before submission to IRBs for approval. The IDI
research department will monitor the study progress
annually.
Dissemination plan for research findings
Dissemination of the results of this study will follow the
institutional dissemination policy (IDI) and national
regulations on data privacy [45]. We aim to publish the
results and present data at national, regional, and inter-
national conferences. The study has been registered with
clinicaltrials.gov (NCT04709159). Since we aim to influ-
ence the TB policy in Uganda and other LMICs, we will
present the results at local meetings with policymakers.
Policy briefs will be presented to the National TB and
Leprosy Program of the Ministry of Health. We will also
conduct community dissemination meetings and com-
municate the results of this study to the participants and
care providers.
Discussion
This study is a multicenter, open-label, randomized con-
trolled trial to determine the impact of IVRT-based
MHI on TB treatment outcomes. The study will com-
pare treatment success at six months in participants with
confirmed drug-susceptible TB randomized to the inter-
vention and control arms. The secondary outcomes in-
clude TB cure rates in participants with pulmonary TB,
appointment keeping, adherence to treatment, and attri-
tion from care. Participants in the intervention arm will
receive adherence and appointment reminders and
health tips and will also have options for reporting
symptoms remotely. We will also use mixed methods to
determine the acceptability of the intervention, its cost-
effectiveness, and its impact on TB treatment outcomes.
This study is not without justification. In 2018, there
were 10 million cases of TB, with 1.45 million deaths,
250,000 of whom were patients living with HIV/AIDS
(PLHIV) [1]. The disease has also harmed other health
sectors [58]. However, whether MHIs can significantly
contribute to a sustainable TB response is unknown.
The growth of the mobile phone industry is highest in
countries with weak health systems and a high burden of
TB [59]. Mobile phone ownership is also high in patients
with TB [19], especially among men, the population
most affected by TB [1, 38]. Therefore, the delivery of
the intervention at the population level is feasible.
In most LMICs, the sine qua non for the success of
MHI is the implementation fidelity and tailoring the
technology to the local context. Previous studies have
demonstrated that technical difficulties are a barrier to
the use and scale-up of MHIs. These include power
outages and sparse network signals, especially in rural
communities [33, 60]. Additionally, only 55% of Uganda
is geographically covered by the Internet [24]. Thus,
MHIs that have previously been demonstrated to be effi-
cacious, including video technology [25], are not imple-
mentable in many LMICs.
To enhance the scale-up of MHIs, the proposed inter-
ventions must be interoperable with existing MHIs and
technologies. To this end, the Ugandan government
requires MHIs to be sustainable, compliant with data
privacy, and interoperability with existing MHIs [61].
The IVRT under investigation meets this requirement as
it is interoperable with DHIS2, the only national data-
base for health reporting in Uganda. Additionally, confi-
dentiality concerns are common among all MHIs. A
study involving the use of IVRT to support the adoption
of TB preventive therapy in Ethiopia has reported confi-
dentiality, stigma, and trust in HCWs as critical determi-
nants of the acceptability of MHIs [33]. However,
concerns about privacy and refusal to participate in
MHIs are generally low in Uganda [28, 62]. The Sharing
of mobile phones outside households is also rare [63].
However, MHIs have an inherent risk of data privacy
breaches that must be mitigated. Therefore, data will be
double-encrypted, system upgrades will be version con-
trolled, and participants will use PIN before receiving re-
minder calls.
Although several frameworks for mobile health appli-
cation development exist, HCD is increasingly preferred
in resource-limited settings [64, 65]. The HCD approach
ensures higher usability of interactive systems by inte-
grating human factors such as human knowledge and
techniques in the prototype development [66]. This
approach has been used to develop other TB health
information systems in sub-Saharan Africa [65]. As em-
phasized by the principles of HCD [64], software devel-
opment involved a multidisciplinary team and broader
stakeholder engagement. Such an approach ensures the
uptake and scaling of MHI in LMICs [32].
We envisage the challenges in the implementation of
this study. In a pilot project that evaluated the use of
IVRT to enhance access to child health care services in
Ghana, the critical barriers to the adoption of the IVRT
were lack of human interaction, lack of refresher train-
ing, and the lack of social integration of the system [35].
Therefore, we will conduct regular refresher training for
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staff. Similarly, the study staff will interview participants
at every study visit and ensure they have no challenges
in using the tool. The software is compatible with
feature phones which have the greatest penetration in
Uganda [67]. On the other hand, the significant reasons
for the success of the pilot project were the ability of the
technology to support local languages, quality of the
service, health education, and empowerment of end-
users. Daftary et al. also reported individualizing MHIs
as an enabler of acceptability [33]. To this end, we will
individualize appointment and adherence reminders by
allowing patients to select the preferred reminder
frequency and their timing. However, contextualizing
intervention is very difficult to achieve in Uganda because
of cultural diversity [68] and limited technology options.
We used several major local languages spoken in Uganda.
Our IVRT allows for two-way communication and there-
fore allows human interaction. In the implementation
phase of the project, we will offer refresher training to
patients and staff on how to use the technology.
Trial status
The initially approved protocol was version 1.3 (version
date: October 07, 2019) but this was superseded by
protocol version 2.0 (version date: March 22, 2021). The
amendments to the protocol in protocol 2.0 added two
additional study sites and provided for phone-based
phone review during the COVID epidemic. The latter is
to ensure there is minimal congestion in health facilities.
Consistent with Uganda Ministry of Health recommenda-
tions for COVID. The CFL-TB trial has received approval
from SOMREC and UNCST. Enrolment for this study
commenced in October 2019 and has so far enrolled 123
of the required 274 participants as of May 15, 2021. Study
enrolment is expected to end in December 2021 and study
results will be available by the end of 2022.
Conclusion
The CFL-U TB study seeks to determine the impact of
IVRT-based MHI on TB treatment outcomes in a high-
burden country. The software aims at addressing the major
operational barriers to the optimization of TB care by lever-
aging technology with a broader reach regardless of literacy
levels. The enrolment of study participants has com-
menced, and preliminary study results will be expected by
the end of 2022. Like other MHIs, we anticipate several
challenges, but these are not insurmountable. The changing
mobile technology ecosystem and the increasing mobile
phone penetration are possible feasible solutions to health
system challenges in most low- and middle-income coun-
tries. However, the impact of such technologies remains to
be determined. While there are design and implementation
limitations, this study addresses a significant public health
problem using a novel hitherto used MHI.
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